Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease

  title={Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease},
  author={Silvia Cermelli and Anna Ruggieri and Jorge Marrero and George N. Ioannou and Laura Beretta},
  journal={PLoS ONE},
MicroRNAs miR-122, miR-34a, miR-16 and miR-21 are commonly deregulated in liver fibrosis and hepatocellular carcinoma. This study examined whether circulating levels of these miRNAs correlate with hepatic histological disease severity in patients with chronic hepatitis C infection (CHC) or non-alcoholic fatty-liver disease (NAFLD) and can potentially serve as circulating markers for disease stage assessment. We first used an in vitro model of hepatitis C virus (HCV) infection to measure the… 

Figures and Tables from this paper

Circulating microRNAs in patients with non-alcoholic fatty liver disease.

NAFLD is associated with altered serum miRNA expression pattern and this study provides clues for defining the non-invasive diagnosis of NAFLD.

Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients

Studied microRNAs could serve as potential early biomarkers for HCC in high-risk groups, with miR-19a as a biomarker for liver fibrosis progression to cirrhosis to HCC.

Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease

Interestingly, receiver operating characteristic (ROC) curve analysis revealed thatmiR-34a and miR-122 are potential markers for discriminating NAFLD patients from healthy controls with an area under the curve (AUC) values of 0.781 and 0.858, respectively.

Circulating microRNA-155 is associated with insulin resistance in chronic hepatitis C patients.

miRNAs as Potential Biomarkers for Viral Hepatitis B and C

The potential use of miRNAs as non-invasive biomarkers to diagnose fibrosis with the intention of prioritizing patients with advanced fibrosis for treatment and surveillance is discussed.

Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma

The serum miR-21 level is a marker for necroinflammatory activity, but does not differ between patients with HCV and HCV-induced HCC.

Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis.

Correlation of miR-122 with Bcl-w is a Paradigm for the Role of Micro RNAs in the Liver Injury Development

Circulating miR-122 is commonly deregulated in liver fibrosis and hepatocellular carcinoma (HCC). In this study we tried to explore the potential usefulness of serum miR-122 as noninvasive diagnostic

Up‐regulation of circulating miR‐20a is correlated with hepatitis C virus‐mediated liver disease progression

Circulating miR‐20a may serve as a potential for predictive biomarker in HCV‐mediated fibrosis and have potential as sensitive and cost‐effective biomarkers for early detection of HCV infection.

Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte‐derived microRNA‐122

It is confirmed that liver injury is associated with high levels of hepatocyte‐derived microRNAs in circulation and demonstrated that in particular miR‐122 is a sensitive marker to distinguish chronic hepatitis C patients from healthy controls.



Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans

A model in which miR-21 targeting of SMAD7 could increase TGF-β signaling, leading to increased fibrogenesis is suggested, further supporting a relationship between mi R-21 and fibrosis.

Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection

The serum level of miR-122 strongly correlates with serum ALT activity and with necroinflammatory activity in patients with chronic HCV infection and elevated ALT levels, but not with fibrosis stage and functional capacity of the liver.

Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma

The addition of miR-16 to conventional serum markers improved sensitivity and specificity for HCC, overall and when analysis was restricted to patients with tumors size smaller than 3 cm.

Circulating MicroRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis

Serum miRNAs presented in serum of patients with HCC and chronic hepatitis have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC, according to Receiver‐operator characteristic (ROC) curve analyses.

Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data

  • F. NegroA. Sanyal
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2009
In patients with chronic HCV infection, steatosis may occur in conjunction with other metabolic risk factors such as insulin resistance and the metabolic syndrome, and this was observed primarily in patients infected with non‐genotype 3 virus.

Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases.

It is suggested that circulating miR-122 has potential as a novel, predictive, and reliable blood marker for viral-, alcohol-, and chemical-induced liver injury.

Serum lipids and their associations with viral levels and liver disease severity in a treatment‐naïve chronic hepatitis C type 1‐infected cohort

In patients with HCV genotype 1 infection, more severe liver disease was associated with lower lipid levels, with the exception of TG levels that were directly related to steatosis.

miR-221 overexpression contributes to liver tumorigenesis

It is shown, using a mouse model of liver cancer, that miR-221 overexpression stimulates growth of tumorigenic murine hepatic progenitor cells, and DNA damage-inducible transcript 4 (DDIT4), a modulator of mTOR pathway, is identified as a bona fide target of miR -221.

Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice

Results show that alterations in the expression of miRNAs are a prominent event during development of NASH induced by methyl deficiency and strongly suggest that severity ofNASH and susceptibility to NASH may be determined by variations in miRNA expression response.

Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C

  • A. Sanyal
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2011
In genotype 1 infection, the presence of hepatic steatosis is a risk factor for failure to respond to pegylated interferon and ribavirin therapy, and efforts to treat insulin resistance prior to antiviral therapy have not been very successful.